← All trials
NCT05167825
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2022
- Primary completion
- Aug 2, 2024
- Completion date
- Mar 17, 2025
- First posted
- Dec 22, 2021
- Last posted
- Dec 7, 2022
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.